FTC Approves Endo-Par Deal Pending Divestments
The FTC has cleared the way for Endo Pharmaceuticals to acquire Par Pharmaceuticals, pending the divestiture of two of its generic drugs.
To resolve anticompetitive concerns, Endo will sell the rights and assets to glycopyrrolate and methimazole tablets to Rising Pharmaceuticals in New Jersey. Used to treat ulcers and overproduction of thyroid hormone, the medications are not commonly produced and, if the drugmakers were allowed to keep them in their post-deal portfolio, costs would likely have been raised, the FTC said Sept. 25.
Under the FTC settlement, Endo will supply Rising Pharmaceuticals with the drugs for two years while it arranges for a third-party manufacturer.
The $8 billion deal, announced in May, will place Endo among the top five firms in the U.S. generics market, adding more than 100 new drugs and more than 200 ANDAs to its offerings (Generic Line, May 27). — Victoria Pelham
Subscribe to Generic Line and save $250 off the regular one-year price of $1,097 — plus receive a FREE copy of our webinar, Success Strategies for Biosimilars Approval: A Roadmap to the 351(k) Application Process — a $287 Value!
LINKS TO KEY DOCUMENTS — Each issue provides you with links that support GEN's articles such as FDA guidances, warning letters, rules, full texts of proposed legislation and more.
FDANEWS DRUG DAILY BULLETIN — This daily email brings you important FDA and international regulatory, legislative and business news in the pharmaceutical industry.
ONLINE ACCESS — Consider our newsletter archive your personal library! Search your current issue — and hundreds of past issues — by keyword and relevancy.
Copyright ©2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing